News & Updates

Lipid parameters tend to get worse during the early remission phase following curative surgery for Cushing’s syndrome (CS), reveals a study.

An association exists between polygenic risk scores (PRS) and diabetes risk, irrespective of traditional risk factors, according to a study in Japanese general populations.

Once-weekly TG103, a novel long-acting GLP-1*/Fc fusion protein, demonstrates noninferiority to dulaglutide in reducing HbA_1c in Chinese patients with type 2 diabetes (T2D) inadequately controlled on metformin, according to a phase III trial presented at EASD 2026.

In the treatment of patients with uncontrolled type 2 diabetes (T2D), adding empagliflozin to the combination of metformin plus evogliptin improves glycaemic control and other metabolic outcomes, as shown in a phase III study conducted in South Korea.

In patients with mild autonomous cortisol secretion (MACS), overnight metyrapone therapy helps to partially retore hypothalamic-pituitary-adrenal (HPA) axis balance and improve sleep and mood, with a favourable tolerability profile, according to a phase II trial.

Subcutaneous injections of olatorepatide, an investigational dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, are associated with up to a 19-percent decrease in body weight and favourable gastrointestinal (GI) tolerability in Chinese adults with overweight or obesity, as shown in the phase III LIGHTEN study.